Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in BJU Int

Retrieve available abstracts of 142 articles:
HTML format

Single Articles

    March 2023
  1. LAZZERI M, Fasulo V, Tinterri C
    Eve's and Adam's rib for prostate cancer screening.
    BJU Int. 2023 Mar 15. doi: 10.1111/bju.15999.

    Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
    BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.

  3. Prostate-specific antigen for prostate cancer screening.
    BJU Int. 2023;131:266.

  4. MOROTE J, Pye H, Campistol M, Celma A, et al
    Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
    BJU Int. 2023 Mar 1. doi: 10.1111/bju.15998.
    PubMed     Abstract available

    February 2023
  5. STROOMBERG HV, Andersen MCM, Helgstrand JT, Larsen SB, et al
    Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result.
    BJU Int. 2023 Feb 27. doi: 10.1111/bju.15997.
    PubMed     Abstract available

  6. MA TM, Czernin J, Felix C, Alano R, et al
    LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
    BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
    PubMed     Abstract available

  7. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    BJU Int. 2023;131:227-235.
    PubMed     Abstract available

    January 2023
    Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in medical prediction.
    BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.

  9. CUSSENOT O, Renard-Penna R, Montagne S, Ondet V, et al
    Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk.
    BJU Int. 2023 Jan 17. doi: 10.1111/bju.15968.
    PubMed     Abstract available

  10. GEBOERS B, Scheltema MJ, Blazevski A, Katelaris A, et al
    Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    BJU Int. 2023 Jan 3. doi: 10.1111/bju.15948.
    PubMed     Abstract available

    December 2022
  11. HANSEN RS, Biorn SH, Birk-Korch JB, Sheikh SP, et al
    Prevalence of prostate cancer in men with haematuria: A systematic review and meta-analysis.
    BJU Int. 2022 Dec 15. doi: 10.1111/bju.15950.
    PubMed     Abstract available

  12. BLAZEVSKI A, Geboers B, Scheltema MJ, Gondoputro W, et al
    Salvage irreversible electroporation for radio recurrent prostate cancer - The prospective FIRE trial.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15947.
    PubMed     Abstract available

  13. SCHELTEMA MJ, Geboers B, Blazevski A, Doan P, et al
    Median 5-year outcomes of primary focal irreversible electroporation for localized prostate cancer.
    BJU Int. 2022 Dec 10. doi: 10.1111/bju.15946.
    PubMed     Abstract available

  14. KOSTER KL, Zumstein V, Suveg K, Jochum W, et al
    Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15847.

  15. BASS EJ, Ahmed HU
    Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3.
    BJU Int. 2022 Dec 5. doi: 10.1111/bju.15859.

  16. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed     Abstract available

    November 2022
  17. HOGENHOUT R, Osses DF, Alberts AR, Buizer-Rijksen HG, et al
    Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
    BJU Int. 2022 Nov 21. doi: 10.1111/bju.15933.
    PubMed     Abstract available

  18. KELLY R, Jensen A, Karunaratna N, Wong S, et al
    PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.

  19. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
    Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
    PubMed     Abstract available

  20. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
    Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
    BJU Int. 2022;130:582-585.

  21. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
    NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
    BJU Int. 2022;130:628-636.
    PubMed     Abstract available

    Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship.
    BJU Int. 2022;130 Suppl 3:4.

  23. YAXLEY WJ, Mackean J, Desai DJ, Tsang G, et al
    Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
    BJU Int. 2022;130 Suppl 3:40-45.
    PubMed     Abstract available

  24. ROBERTS MJ, Chatfield MD, Hruby G, Nandurkar R, et al
    Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    BJU Int. 2022;130 Suppl 3:32-39.
    PubMed     Abstract available

    September 2022
  25. ELDRED-EVANS D, Connor MJ, Bertoncelli Tanaka M, Bass E, et al
    The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.
    BJU Int. 2022 Sep 22. doi: 10.1111/bju.15899.
    PubMed     Abstract available

  26. VEERMAN H, Donswijk M, Bekers E, Bodar YJL, et al
    The Oncological Characteristics of Non-PSMA-Expressing Primary Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2022 Sep 19. doi: 10.1111/bju.15896.

  27. EHRET F, Hofmann T, Furweger C, Kufeld M, et al
    Single-fraction PSMA-PET- and multiparametric MRI-guided SBRT for Prostate Cancer Local Recurrences.
    BJU Int. 2022 Sep 17. doi: 10.1111/bju.15894.
    PubMed     Abstract available

  28. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or coexistence?
    BJU Int. 2022 Sep 12. doi: 10.1111/bju.15074.

  29. ORRASON AW, Styrke J, Garmo H, Stattin P, et al
    Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
    BJU Int. 2022 Sep 11. doi: 10.1111/bju.15891.
    PubMed     Abstract available

  30. ICZKOWSKI KA, Molina M, Egevad L, Bostwick DG, et al
    Low-Grade Prostate Cancer Should Still be Labeled Cancer.
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15886.

  31. ONG S, Chen K, Grummet J, Yaxley J, et al
    Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus?
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15883.
    PubMed     Abstract available

  32. MEIJER D, Ettema RH, van Leeuwen PJ, van der Kwast TH, et al
    The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    BJU Int. 2022 Sep 7. doi: 10.1111/bju.15881.
    PubMed     Abstract available

  33. Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.

  34. RAHOTA RG, Salin A, Gautier JR, Almeras C, et al
    A prehabilitation programme implemented before robot-assisted radical prostatectomy improves peri-operative outcomes and continence recovery.
    BJU Int. 2022;130:357-363.
    PubMed     Abstract available

    August 2022
  35. EXTERKATE L, Wegelin O, Barentsz JO, van der Leest MG, et al
    Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    BJU Int. 2022 Aug 22. doi: 10.1111/bju.15876.
    PubMed     Abstract available

  36. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
    Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
    BJU Int. 2022;130:181-185.

    July 2022
  37. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
    Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
    BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.

  38. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
    Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
    BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
    PubMed     Abstract available

  39. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.

  40. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
    Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
    BJU Int. 2022;130:84-91.
    PubMed     Abstract available

  41. SETIA SA, Smith J, Cendo D, Yoder J, et al
    Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    BJU Int. 2022;130:54-61.
    PubMed     Abstract available

    June 2022
  42. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed     Abstract available

  43. AGGARWAL A, Han L, Tree A, Lewis D, et al
    Impact of centralisation of prostate cancer services on the choice of radical treatment.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
    PubMed     Abstract available

  44. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.

  45. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed     Abstract available

  46. LANGLEY S, Eden C, Perry M, Patil K, et al
    Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
    BJU Int. 2022;129:731-736.
    PubMed     Abstract available

    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.

  48. PERRY E, Talwar A, Taubman K, Ng M, et al
    Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    BJU Int. 2022;130 Suppl 1:28-36.
    PubMed     Abstract available

    May 2022
  49. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
    PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
    BJU Int. 2022 May 16. doi: 10.1111/bju.15773.

  50. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
    Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    BJU Int. 2022;129:621-626.
    PubMed     Abstract available

  51. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
    'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
    BJU Int. 2022;129:591-600.
    PubMed     Abstract available

    April 2022
  52. NATHAN A, Morris M, Parry MG, Berry B, et al
    Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
    PubMed     Abstract available

  53. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
    Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
    PubMed     Abstract available

  54. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
    Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
    BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
    PubMed     Abstract available

  55. LANE JA, Donovan JL, Young GJ, Davis M, et al
    Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
    PubMed     Abstract available

  56. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
    Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
    PubMed     Abstract available

  57. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
    High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
    BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.

  58. Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
    BJU Int. 2022;129:422.

  59. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
    Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    BJU Int. 2022;129:524-533.
    PubMed     Abstract available

    March 2022

  60. New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
    BJU Int. 2022;129:304-305.

  61. KLEIN RJ
    Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    BJU Int. 2022;129:271.

  62. FERRARO S, Biganzoli EM
    Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
    BJU Int. 2022;129:418.

  63. MARTIN RM, Dixon P, Turner E, Keeney E, et al
    Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
    BJU Int. 2022;129:269-270.

  64. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
    Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
    BJU Int. 2022;129:337-344.
    PubMed     Abstract available

  65. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
    The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
    BJU Int. 2022;129:318-324.
    PubMed     Abstract available

  66. ZHAO J, Sun G, Zhu S, Dai J, et al
    Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    BJU Int. 2022;129:345-355.
    PubMed     Abstract available

  67. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
    Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    BJU Int. 2022;129:280-289.
    PubMed     Abstract available

    February 2022
  68. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
    Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
    BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
    PubMed     Abstract available

  69. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
    Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
    BJU Int. 2022;129:194-200.
    PubMed     Abstract available

  70. SORCE G, Stabile A, Luciano R, Motterle G, et al
    Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    BJU Int. 2022;129:201-207.
    PubMed     Abstract available

    January 2022
  71. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
    Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
    PubMed     Abstract available

  72. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
    Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.

  73. BRATT O
    Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
    BJU Int. 2022;129:3-4.

  74. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed     Abstract available

    December 2021
  75. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
    Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
    BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
    PubMed     Abstract available

  76. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
    BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
    PubMed     Abstract available

  77. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
    Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
    PubMed     Abstract available

  78. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.

  79. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.

  80. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed     Abstract available

  81. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed     Abstract available

    November 2021
  82. JOHN JB, Pascoe J, Fowler S, Walton T, et al
    A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
    PubMed     Abstract available

  83. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
    Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
    PubMed     Abstract available

  84. LEE V, An Y, Park HS, Yu JB, et al
    Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
    BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
    PubMed     Abstract available

  85. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
    Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
    BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
    PubMed     Abstract available

  86. HOFBAUER SL, Luger F, Harland N, Plage H, et al
    A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
    BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
    PubMed     Abstract available

  87. IP CCK, Kealey J, Davis ID, Sengupta S, et al
    Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
    BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
    PubMed     Abstract available

  88. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
    Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
    PubMed     Abstract available

  89. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.

  90. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed     Abstract available

  91. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed     Abstract available

    October 2021
  92. HUYNH LM, Huang E, Towe M, Liang K, et al
    Evidence for integration of total and free testosterone levels in management of prostate cancer.
    BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
    PubMed     Abstract available

  93. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
    The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
    PubMed     Abstract available

  94. WITT JH, Friedrich M, Jandrig B, Porsch M, et al
    Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
    BJU Int. 2021 Oct 17. doi: 10.1111/bju.15618.
    PubMed     Abstract available

  95. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.

  96. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.

  97. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.

  98. KELLY R, Anton A, Wong S, Shapiro J, et al
    Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
    BJU Int. 2021;128 Suppl 1:18-26.
    PubMed     Abstract available

  99. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
    Outcomes of the RAFT trial: robotic surgery after focal therapy.
    BJU Int. 2021;128:504-510.
    PubMed     Abstract available

    September 2021
  100. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
    The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
    BJU Int. 2021;128:298-300.

    August 2021
  101. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed     Abstract available

  102. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
    BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
    PubMed     Abstract available

  103. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed     Abstract available

  104. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
    Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
    BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
    PubMed     Abstract available

  105. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
    BJU Int. 2021;128:127-130.

    Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
    BJU Int. 2021;128:125-126.

  107. INOUE T, Sasaki T, Kato M, Masui S, et al
    Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
    PubMed     Abstract available

  108. Chemotherapeutic treatment of MCRPC and non-MCRPC.
    BJU Int. 2021;128:153-154.

  109. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
    Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
    BJU Int. 2021;128:165-167.

    July 2021
  110. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
    Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
    BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
    PubMed     Abstract available

  111. KAMRAN SC, Zietman AL
    Radiation Treatment in Prostate Cancer: Covering the Waterfront.
    BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
    PubMed     Abstract available

  112. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed     Abstract available

  113. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
    The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
    BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
    PubMed     Abstract available

  114. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
    Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
    BJU Int. 2021;128:103-111.
    PubMed     Abstract available

  115. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
    Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    BJU Int. 2021;128:72-78.
    PubMed     Abstract available

    June 2021
  116. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
    Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
    BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
    PubMed     Abstract available

  117. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
    Prostate cancer in transgender women: what does a urologist need to know?
    BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
    PubMed     Abstract available

    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.

  119. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.

  120. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.

  121. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
    Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
    BJU Int. 2021;127:729-741.
    PubMed     Abstract available

  122. DINNEEN E, Haider A, Grierson J, Freeman A, et al
    NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
    BJU Int. 2021;127:676-686.
    PubMed     Abstract available

    May 2021
  123. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed     Abstract available

  124. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed     Abstract available

  125. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed     Abstract available

  126. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
    Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
    BJU Int. 2021 May 11. doi: 10.1111/bju.15366.

  127. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.

  128. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.

  129. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed     Abstract available

  130. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed     Abstract available

  131. TIMM B, Farag M, Liodakis P, Angus D, et al
    Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    BJU Int. 2021;127 Suppl 1:23-29.
    PubMed     Abstract available

  132. JOHN A, John H, Catterwell R, Selth LA, et al
    Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
    BJU Int. 2021;127 Suppl 1:13-22.
    PubMed     Abstract available

    April 2021
  133. CHILUKURI S, Murthy V
    Adjuvant radiation for prostate cancer: Too early to abandon?
    BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
    PubMed     Abstract available

  134. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
    BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
    PubMed     Abstract available

  135. XU AJ, Taylor J, Gao T, Mihalcea R, et al
    TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
    BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
    PubMed     Abstract available

  136. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
    Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
    BJU Int. 2021;127:412-417.
    PubMed     Abstract available

    March 2021
  137. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.

  138. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed     Abstract available

    February 2021
  139. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed     Abstract available

    January 2021
  140. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.

  141. World News.
    BJU Int. 2021;127:1-3.

  142. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.